US Senator

Jeanne Shaheen Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB266

Introduced
1/28/25  
Dr. Lorna Breen Health Care Provider Protection Reauthorization Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB272

Introduced
1/28/25  
Protect Infant Formula from Contamination ActThis bill imposes certain new requirements on infant formula manufacturers and the Food and Drug Administration (FDA) following the discovery of contaminated, adulterated, or misbranded infant formula. Specifically, the bill requires infant formula manufacturers to report to the FDA within one business day of learning that formula that was processed by the manufacturer but that is no longer within the manufacturer’s control may not provide required nutrients or may be otherwise adulterated or misbranded. Further, if any testing of finished infant formula reveals the presence of specified microorganisms (e.g., salmonella), the manufacturer must notify the FDA within one business day. (Under current law, manufacturers are only required to report contamination to the FDA if the affected formula has left the manufacturer’s control.) The manufacturer must also promptly provide the test results to the FDA and consult with the FDA on proper isolation and disposal of the affected product. The FDA must respond to such a notification and begin discussing proper investigative and corrective action with the manufacturer within one business day. Within 90 days of a report of adulterated, misbranded, or contaminated infant formula, the FDA must determine whether the manufacturer that reported the problem has performed, or is performing, appropriate investigative and corrective action. Finally, the FDA is required to periodically report on the infant formula supply chain and efforts to improve the safety and supply of infant formula, and must consult with other federal agencies and infant formula stakeholders on these issues.  
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB297

Introduced
1/29/25  
PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB300

Introduced
1/29/25  
Refer
1/29/25  
DLARA Disaster Loan Accountability and Reform Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB305

Introduced
1/29/25  
Small Business Technological Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB315

Introduced
1/29/25  
Refer
1/29/25  
AM Radio for Every Vehicle Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB317

Introduced
1/29/25  
Charitable Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB331

Introduced
1/30/25  
Refer
1/30/25  
Report Pass
2/27/25  
HALT Fentanyl Act Halt All Lethal Trafficking of Fentanyl Act

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB280

Introduced
1/28/25  
Global Health, Empowerment and Rights Act
US

Us Congress 2025-2026 Regular Session

Us Congress Senate Bill SB329

Introduced
1/30/25  
Keeping Drugs Out of Schools Act of 2025This bill allows the Office of National Drug Control Policy to award grants for eligible entities to implement school-community partnerships for preventing and reducing substance use and misuse among youth. Eligible entity refers to a coalition that (1) receives or has received a grant under the Drug-Free Communities Support Program, and (2) has a memorandum of understanding in effect with not less than one local school to establish a school-community partnership.